Clinician Link.AI ™️’s Post

🎥 Join Dr. Peter Kaiser as he delves into the significant advancements in ophthalmic treatment with the introduction of Bayer | Ophthalmology 8 mg aflibercept. Discover how this higher dosage is making strides in patient care, allowing for extended treatment intervals and improved outcomes, especially for those with challenging cases. Dr. Kaiser shares his experiences and the promising results observed in two distinct patient groups, showcasing the drug's versatility and effectiveness. Tune in to gain valuable insights into this groundbreaking development in ophthalmology! #COPHY2024 #Aflibercept8mg #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress

🌟 Dive into the insights of Dr. Anat Loewenstein as she discusses the findings of the Barometer Study - research made possible with the support of Bayer | Ophthalmology - a global survey aimed at understanding patient needs and healthcare practitioner awareness in ophthalmology. Discover the surprising revelations about clinic accessibility, staff knowledge gaps, and patient communication. Dr. Loewenstein's discussion sheds light on crucial areas needing attention in eye care, sparking conversations on how to enhance patient experience and staff education. Join us for this eye-opening session! #COPHY2024 #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress Simrat Sodhi Anat Loewenstein Vision Academy

🔬💡 Dr. David Eichenbaum discusses the significant benchmarks in visual acuity improvements that could change treatment approaches for wet macular degeneration. He emphasizes that an improvement of five or six letters could lead to a straightforward adoption of new treatments, providing a clear benefit to patients. The key is achieving a balance where the benefits justify additional treatments. Tune in as we explore how these clinical outcomes could potentially set new standards in ophthalmology. #ClinicalTrials #Ophthalmology #PatientCare RIWC24: Retina International World Congress 2024

👁️🔬 Dr. David Eichenbaum shares groundbreaking findings from his study on aflibercept high dose (EYLEA® HD (aflibercept) Injection HCP 8mg) in treating wet AMD. As the first real-world data set, the study reveals that while a significant portion of patients responded positively, extending treatment intervals, a segment still required more frequent care. This pivotal research highlights the importance of personalized medicine in ophthalmology, as responses vary widely among patients. Discover more about how these insights are shaping future treatment protocols. #ASRS2024 #Ophthalmology #MedicalLeadership #VisionaryInOphthalmology #MedicalInnovation #RetinaSpecialists #EyeCareInnovation #VisionScience #MedTech #HealthcareTrends #ClinicalResearch ASRS – American Society of Retina Specialists Bayer Bayer | Ophthalmology Saghar Bagheri MD PhD

Unlock Mondays with an exciting publication! Are you interested in the factors influencing fluid resolution in neovascular age-related macular degeneration? Check out the publication 'Fluid Resolution Without Shortening Injection Interval During Subretinal Fluid-tolerating Treatment in Neovascular Age-related Macular Degeneration.' This study investigates the incidence of subretinal fluid resolution during treatment while maintaining injection intervals. What implications do these findings have for managing treatment strategies in AMD? Stay informed with the latest developments in ophthalmology. Discover it: https://lnkd.in/dwbFu6dB #Ophthalmology #Publication #NeovascularAMD #SubretinalFluid #TreatmentStrategies

Patients with neovascular #AgeRelatedMacularDegeneration (nAMD) undergoing treat-and-extend #Faricimab therapy can maintain vision gains through 2 years, according to investigators of 2 global phase 3 clinical trials published in Ophthalmology (American Academy of Ophthalmology). Approximately 80% of participants who were managed faricimab reached 12 week dosing or longer. This is significant as treat-and-extend-based personalized treatment interval (T&E-based PTI) most closely mirrors real-world practice, according to the report. Read more: https://brnw.ch/21wItuu #NeovascularAgedRelatedMacularDegeneration #nAMD #Faricimab #ClinicalTrials #Ophthalmology #EyeHealth #EyeCare #Ophthalmology

An assessment of patients with Central Retinal Artery Occlusion published in the American Journal of Ophthalmology ! - Most present within 24 hours of symptoms and with elevated inflammatory makers - Visual recovery and reperfusion are possible, both with and without the presence of a cilioretinal artery - Total and inner retinal thickening was observed on OCT at presentation, with subsequent progressive retinal thinning stabilizing after 6 months. - This modern data set can serve as a comprehensive baseline analysis for future interventional trials Great work by Sandra Hoyek and thanks to the mentorship of Demetrios Vavvas on the project! https://lnkd.in/esB_-Ub3

I am thrilled to share our recent publication in the International Ophthalmology, titled "Clinical Characteristics and Management Outcome of Acute Infectious Endophthalmitis." Our study, a comprehensive retrospective chart review from 2017 to 2022, analyzed the demographics, clinical characteristics, and treatment outcomes of 182 patients with acute infectious endophthalmitis (AIE). We found that post-operative AIE was the most prevalent type, constituting 60% of cases, with phacoemulsification being the most common preceding surgery. Despite the severe visual impairment associated with AIE, our results highlight that timely and appropriate interventions can lead to significant visual recovery. Read more about our findings in the full article! https://lnkd.in/eZtjaphQ

Glaucoma stands as the leading cause of permanent vision loss, affecting approximately 80 million people in 2020, with projections indicating a rise to 112 million by 2040. * World Glaucoma Week is an opportunity to promote regular eye screenings for early diagnosis and treatment, as well as to tackle nonadherence in glaucoma patients to prevent irreversible blindness worldwide. Find out more about open angle glaucoma risk factors and treatment by watching this Viatris educational video. #worldglaucomaweek #Glaucoma #GlaucomaTreatment #Ophthalmology #viaViatris *European Glaucoma Society Terminology and Guidelines for Glaucoma. 5th Edition British Journal of Ophthalmology.

Most viewed in the last 7 days from JAMA Ophthalmology: In-office suprachoroidal viscopexy (SCVEXY) for primary acute rhegmatogenous retinal detachment showed promising results, with 5 out of 6 patients achieving successful reattachment without additional procedures. https://ja.ma/3ZO6HJj